INDICATION FOR THERAPY IN MULTIPLE MYELOMA: SHOULD IT BE STAGE OR STABILITY?
- 27 July 1985
- journal article
- other
- Published by Elsevier in The Lancet
- Vol. 326 (8448), 210
- https://doi.org/10.1016/s0140-6736(85)91518-1
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phaseBritish Journal of Haematology, 1984
- Critical Study of Staging in Multiple MyelomaScandinavian Journal of Haematology, 1983
- Biosynthesis of Immunoglobulin in Human Immunoproliferative DiseasesActa Haematologica, 1982
- REAPPRAISAL OF PLATEAU PHASE IN MYELOMAThe Lancet, 1980
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myelomaBlood, 1980
- Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myelomaInternational Journal of Cancer, 1979
- Prognostic factors in multiple myelomaCancer, 1975
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- PART I. ANALYSIS OF PRESENTING FEATURES OF PROGNOSTIC IMPORTANCEBritish Journal of Haematology, 1973
- Growth Rates and Responses to Treatment in Human MyelomatosisBritish Journal of Haematology, 1969